Novavax, Inc. - Product Pipeline Review - 2015

Published: Jun, 2015 | Pages: 48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Novavax, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Novavax, Inc. - Product Pipeline Review - 2015', provides an overview of the Novavax, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Novavax, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Novavax, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Novavax, Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Novavax, Inc.'s pipeline products

Reasons to buy

- Evaluate Novavax, Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Novavax, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Novavax, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Novavax, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Novavax, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Explore the dormant and discontinued projects of Novavax, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Novavax, Inc. Snapshot 5
Novavax, Inc. Overview 5
Key Information 5
Key Facts 5
Novavax, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Novavax, Inc. - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Pipeline Products - Combination Treatment Modalities 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Novavax, Inc. - Pipeline Products Glance 13
Novavax, Inc. - Late Stage Pipeline Products 13
Phase III Products/Combination Treatment Modalities 13
Novavax, Inc. - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Novavax, Inc. - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Novavax, Inc. - Drug Profiles 17
influenza (trivalent) virus like particle vaccine 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
influenza (quadrivalent) virus like particle vaccine 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
influenza [strain H7N9] (monovalent) virus like particle vaccine 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
respiratory syncytial virus vaccine 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
rabies vaccine 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
ebola vaccine 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
MERS-CoV Vaccine 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
respiratory syncytical virus + influenza vaccine 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
SARS-CoV Vaccine 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Novavax, Inc. - Pipeline Analysis 30
Novavax, Inc. - Pipeline Products by Target 30
Novavax, Inc. - Pipeline Products by Route of Administration 31
Novavax, Inc. - Pipeline Products by Molecule Type 32
Novavax, Inc. - Recent Pipeline Updates 33
Novavax, Inc. - Dormant Projects 44
Novavax, Inc. - Company Statement 45
Novavax, Inc. - Locations And Subsidiaries 46
Head Office 46
Other Locations & Subsidiaries 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

List of Tables

Novavax, Inc., Key Information 5
Novavax, Inc., Key Facts 5
Novavax, Inc. - Pipeline by Indication, 2015 7
Novavax, Inc. - Pipeline by Stage of Development, 2015 8
Novavax, Inc. - Monotherapy Products in Pipeline, 2015 9
Novavax, Inc. - Combination Treatment Modalities in Pipeline, 2015 10
Novavax, Inc. - Partnered Products in Pipeline, 2015 11
Novavax, Inc. - Partnered Products/ Combination Treatment Modalities, 2015 12
Novavax, Inc. - Phase III, 2015 13
Novavax, Inc. - Phase II, 2015 14
Novavax, Inc. - Phase I, 2015 15
Novavax, Inc. - Preclinical, 2015 16
Novavax, Inc. - Pipeline by Target, 2015 30
Novavax, Inc. - Pipeline by Route of Administration, 2015 31
Novavax, Inc. - Pipeline by Molecule Type, 2015 32
Novavax, Inc. - Recent Pipeline Updates, 2015 33
Novavax, Inc. - Dormant Developmental Projects,2015 44
Novavax, Inc., Other Locations 46
Novavax, Inc., Subsidiaries 46